Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Pembrolizumab +/- Bevacizumab in Metastatic Cervical Cancer
NCT07216703Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Primary completion
- Oct 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in Cervical Cancer (CC), sponsored by Merck & Co.. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07216703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216703.